Literature DB >> 28612463

Meta-analysis of the predictive value of DNA aneuploidy in malignant transformation of oral potentially malignant disorders.

Nader A Alaizari1, Marcelo Sperandio2, Edward W Odell3, Daiane Peruzzo2, Sadeq A Al-Maweri1.   

Abstract

DNA aneuploidy is an imbalance of chromosomal DNA content that has been highlighted as a predictor of biological behavior and risk of malignant transformation. To date, DNA aneuploidy in oral potentially malignant diseases (OPMD) has been shown to correlate strongly with severe dysplasia and high-risk lesions that appeared non-dysplastic can be identified by ploidy analysis. Nevertheless, the prognostic value of DNA aneuploidy in predicting malignant transformation of OPMD remains to be validated. The aim of this meta-analysis was to assess the role of DNA aneuploidy in predicting malignant transformation in OPMD. The questions addressed were (i) Is DNA aneuploidy a useful marker to predict malignant transformation in OPMD? (ii) Is DNA diploidy a useful negative marker of malignant transformation in OPMD? These questions were addressed using the PECO method. Five studies assessing aneuploidy as a risk marker of malignant change were pooled into the meta-analysis. Aneuploidy was found to be associated with a 3.12-fold increased risk to progress into cancer (RR=3.12, 95% CI 1.86-5.24). Based on the five studies meta-analyzed, "no malignant progression" was more likely to occur in DNA diploid OPMD by 82% when compared to aneuploidy (RR=0.18, 95% CI 0.08-0.41). In conclusion, aneuploidy is a useful marker of malignant transformation in OPMD, although a diploid result should be interpreted with caution.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  aneuploidy; diploidy; malignant transformation; meta-analysis

Mesh:

Substances:

Year:  2017        PMID: 28612463     DOI: 10.1111/jop.12603

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  7 in total

1.  Full Karyotype Interphase Cell Analysis.

Authors:  Adi Baumgartner; Christy Ferlatte Hartshorne; Aris A Polyzos; Heinz-Ulrich G Weier; Jingly Fung Weier; Ben O'Brien
Journal:  J Histochem Cytochem       Date:  2018-04-19       Impact factor: 2.479

2.  Predicting Progression of Low-Grade Oral Dysplasia Using Brushing-Based DNA Ploidy and Chromatin Organization Analysis.

Authors:  Madhurima Datta; Denise M Laronde; Miriam P Rosin; Lewei Zhang; Bertrand Chan; Martial Guillaud
Journal:  Cancer Prev Res (Phila)       Date:  2021-08-10

3.  Application of 5-aminolevulinic acid-mediated Waterlase-assisted photodynamic therapy in the treatment of oral leukoplakia.

Authors:  Jiali Ou; Yijun Gao; Huan Li; Tianyou Ling; Xiaoyan Xie
Journal:  Sci Rep       Date:  2022-06-07       Impact factor: 4.996

4.  Clinical Evaluation of the Optical Filter for Autofluorescence Glasses for Oral Cancer Curing Light Exposed (GOCCLES®) in the Management of Potentially Premalignant Disorders: A Retrospective Study.

Authors:  Carlo Lajolo; Mariateresa Tranfa; Romeo Patini; Antonino Fiorino; Teresa Musarra; Roberto Boniello; Alessandro Moro
Journal:  Int J Environ Res Public Health       Date:  2022-05-04       Impact factor: 4.614

5.  DNA aneuploidy with image cytometry for detecting dysplasia and carcinoma in oral potentially malignant disorders: A prospective diagnostic study.

Authors:  Chenxi Li; Lan Wu; Yiwen Deng; Xuemin Shen; Wei Liu; Linjun Shi
Journal:  Cancer Med       Date:  2020-07-07       Impact factor: 4.452

6.  Recurrent copy number alterations involving EGFR, CDKN2A, and CCND1 in oral premalignant lesions.

Authors:  Fredrik Jäwert; André Fehr; Jenny Öhman; Göran Stenman; Göran Kjeller
Journal:  J Oral Pathol Med       Date:  2022-05-20       Impact factor: 3.539

7.  Prediction of malignant transformation in oral epithelial dysplasia using infrared absorbance spectra.

Authors:  Barnaby G Ellis; Conor A Whitley; Asterios Triantafyllou; Philip J Gunning; Caroline I Smith; Steve D Barrett; Peter Gardner; Richard J Shaw; Peter Weightman; Janet M Risk
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.